What Is Peptide Therapy?

Peptide Therapy Defined

What is a peptide?

A peptide is a short chain of amino acids, typically 2 to 50, linked by peptide bonds. Below 50 amino acids, a chain is a peptide; above that, it is a protein. Natural examples include insulin (technically a small protein at 51 amino acids), oxytocin (9), and glucagon (29).

In therapeutic contexts, peptides are synthesized pharmaceutically to replicate or analog a naturally occurring signaling molecule. Because most peptides interact with specific cellular receptors, they are generally highly selective, which tends to produce narrowly targeted effects (PMID 25450771).

How peptides signal the body

Peptides work primarily by binding to cell-surface receptors, triggering downstream cascades that modulate gene expression, protein synthesis, or secretion of other hormones. Examples:

• Sermorelin binds the GHRH receptor on the pituitary, stimulating endogenous growth hormone release (PMID 18031173).
• Semaglutide binds the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing food intake (PMID 29617641). Natural GLP-1 is broken down within minutes in the blood, whereas semaglutide is modified to have a half-life of about 7 days, long enough for once-weekly dosing (PMID 29915923)).
• Based mainly on animal studies, BPC-157 is thought to interact with the nitric oxide system and to promote healing at sites of tissue damage (PMID 23755725).

Growth hormone secretagogues stimulate the body's own pulsatile GH release, which remains subject to negative feedback, a key distinction from direct GH replacement (PMID 28400207).

Therapeutic vs. performance vs. research peptides

Three categories dominate the conversation:

• Therapeutic peptides: FDA-approved or compounded for specific clinical indications, prescribed by a licensed clinician.
• Performance peptides, prescribed (or self-sourced) for athletic and physique outcomes; regulatory status varies.
• Research peptides, sold explicitly for research use only, are not for human consumption; this market is unregulated, and testing of unregulated performance-enhancing products, including peptide hormones, has found widespread mislabeling (PMID 28156209).

The Peptide Association works only with providers and pharmacies operating within the therapeutic category.

How Peptide Therapy Works

Receptor binding and biological cascades

When a peptide binds its target receptor, it triggers a specific cascade, often involving G-protein coupled signaling, enzyme activation, or ion channel modulation. This is why peptide therapy can produce relatively targeted effects, although selectivity varies by compound: in animal studies, some growth hormone-releasing peptides also raised ACTH and cortisol, while ipamorelin released GH without those effects and none altered reproductive hormones (PMID 9849822).

Administration routes

Most therapeutic peptides are administered via:

• Subcutaneous injection (most common), reliable absorption, patient-administered after training.
• Intramuscular injection, used for specific protocols.
• Intranasal spray, for compounds like oxytocin; bremelanotide (PT-141), by contrast, is approved as a self-administered subcutaneous injection (PMID 31429064).
• Oral, limited bioavailability for most peptides; an exception is oral semaglutide (Rybelsus), which is co-formulated with the absorption enhancer SNAC and absorbed in the stomach (PMID 30429357).
• Transdermal, emerging formulations, indication-specific.

Route matters because peptides are typically degraded in the digestive tract, which is why oral administration is not the default for systemic peptide effects.

Why peptides are typically prescribed by a clinician

Dosing, cycling, route selection, compound combination, and monitoring all require clinical judgment. Peptides bought from unregulated online sellers can be mislabeled and contaminated; in one test-purchase study, semaglutide vials from illegal online pharmacies had incorrect content, low purity, and endotoxin contamination (PMID 39509151). A licensed clinician provides the workup, sourcing oversight, and ongoing lab monitoring that makes therapy safe and trackable.

Common Peptides Used in Therapy

BPC-157, tissue repair, gut health

Body Protection Compound 157, derived from a protective sequence in human gastric juice (PMID 21030672). Commonly used for tendinopathy, ligamentous injury, and gastrointestinal inflammation. See the BPC-157 clinician's guide for a full breakdown.

Sermorelin, growth hormone secretagogue

A 29-amino-acid fragment of GHRH that stimulates endogenous growth hormone release (PMID 18031173). Often used for age-related GH decline, sleep optimization, and body composition protocols. See sermorelin peptide therapy.

Semaglutide and tirzepatide, metabolic, GLP-1

Semaglutide and tirzepatide, metabolic: FDA-approved incretin-based drugs (semaglutide as Wegovy/Ozempic, a GLP-1 receptor agonist; tirzepatide as Zepbound/Mounjaro, a dual GIP and GLP-1 receptor agonist) (PMID 35658024)). Widely used for type 2 diabetes and chronic weight management. In the SURMOUNT-1 trial, adults with obesity taking weekly tirzepatide lost an average of 15% to 21% of body weight over 72 weeks, depending on dose, against 3% on placebo (Jastreboff et al., NEJM, 2022 (PMID 35658024)).

CJC-1295 / Ipamorelin, growth hormone axis

Often stacked with sermorelin or each other. CJC-1295 is a long-acting GHRH analog that raises GH for days after one injection, while ipamorelin released GH in animal studies without the ACTH and cortisol rise seen with older GH-releasing peptides (PMID 9849822).

PT-141 (Bremelanotide), sexual health

A melanocortin receptor agonist (PMID 31429064). FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women; use in men and for other indications is off-label (PMID 31429064).

Thymosin alpha-1, immune modulation

Approved in some countries outside the U.S (PMID 19392576). ((as Zadaxin), mainly for chronic hepatitis B and C; not FDA-approved (PMID 19392576). Under investigation for immune support in chronic infection and autoimmune contexts.

Browse the full peptide database for research summaries, dosing references, and regulatory notes on every tracked compound.

Conditions Peptide Therapy Is Being Used For

Tissue repair and injury recovery

BPC-157 and thymosin beta-4 (including its fragment TB-500) are marketed for tendon, ligament, and post-surgical recovery, but their tissue-repair benefits come mainly from animal studies and rigorous human data are scarce (PMID 41966639).

Metabolic health and weight management

GLP-1 agonists have fundamentally changed the metabolic medicine landscape and are increasingly integrated with other peptides in protocolized care.

Age-related decline (hormone optimization)

Growth hormone secretagogues are prescribed in some clinics for the somatopause, the age-related decline in GH and IGF-1 that accompanies catabolic changes of aging, although GH therapy for this purpose has produced only minor body-composition changes and most endocrinologists do not recommend it (PMID 42308660).

Immune dysregulation

Thymosin alpha-1 has been studied in chronic viral hepatitis, severe infections such as sepsis, and as an immune adjuvant during chemotherapy (PMID 19392576).

Neurocognitive support

Dihexa, cerebrolysin, and selank are marketed or investigated for cognition, but evidence quality varies widely, and several such nootropic peptides are sold online as research peptides without completed clinical trials (PMID 31667971).

What peptide therapy is NOT

Peptide therapy is not a universal solution. It does not replace primary care, it does not cure disease in most cases, and it cannot compensate for undiagnosed underlying conditions. A good peptide protocol works within a broader framework of labs, lifestyle, and conventional medicine.

Is Peptide Therapy Safe?

The importance of sourcing from a compounding pharmacy

Sourcing is a major safety variable in peptide therapy. 503A compounding pharmacies fill patient-specific prescriptions under state board of pharmacy oversight, while 503B outsourcing facilities, created by the 2013 Drug Quality and Security Act, face additional FDA oversight and can compound in larger batches (PMID 30005109). Both are legitimate channels, the Peptide Association supplier network verifies sourcing for every protocol our clinician network approves.

Why provider credentials matter

Licensed clinicians bring three things non-licensed providers cannot: appropriate workup, individualized dosing, and ongoing monitoring.

Common side effects and contraindications

Human safety data are limited for many peptides; reported adverse effects of GH-axis peptides include injection-site reactions, fluid retention, joint aches, altered glucose metabolism, and hormonal changes, alongside compound-specific contraindications (PMID 42395176). Active malignancy, pregnancy, and certain cardiovascular conditions are common exclusions.

Red flags when choosing a provider

• No labs before starting therapy
• Sourcing that is vague, offshore, or described as “research grade”
• Pressure to commit to long-term contracts before a workup
• No ongoing follow-up built into the program
• One-size-fits-all dosing regardless of patient

Regulatory Status in the United States

FDA framework for peptides

Peptides occupy a complex regulatory position. Some, like semaglutide and tirzepatide, are FDA-approved finished drug products (PMID 41393574). Others have no FDA-approved product and are available only when a licensed pharmacy compounds them for an individual patient's prescription, where FDA rules permit. A handful have been specifically restricted or placed on the FDA Bulks List with conditions.

Compounding pharmacy oversight

503A pharmacies are overseen mainly by state boards of pharmacy and must meet federal compounding conditions; 503B outsourcing facilities, created by the 2013 Drug Quality and Security Act, face additional FDA oversight and cGMP requirements (PMID 30005109). Legitimate compounded peptide therapy routes through one of these two channels.

Recent 2026 regulatory updates

The regulatory landscape shifts regularly. See the Peptide Association regulatory tracker for current status of individual compounds and state-level rule changes.

What Peptide Therapy Costs

Typical cost ranges per compound

Monthly costs for common protocols:

• Tissue-repair peptides (BPC-157, TB-500): $150–$400/month
• Growth hormone secretagogues (sermorelin, CJC/Ipamorelin): $200–$500/month
• GLP-1 agonists: varies significantly; branded products are $500–$1,300/month cash-pay, compounded versions lower
• PT-141: $150–$300/month
• Comprehensive protocols with multiple compounds: $500–$1,500/month

Insurance considerations

Most peptides are not covered by commercial insurance outside of approved indications. GLP-1 agonists may be covered for type 2 diabetes; specific formulations may have coverage paths for other conditions. Assume cash-pay for initial consultation and most ongoing therapy.

Cash-pay vs. concierge care models

Peptide clinics fall along a spectrum from pay-per-visit discount telehealth (low cost, limited monitoring) to concierge care that bundles labs, peptides, and provider access for a flat monthly fee. Fit depends on how much ongoing coordination a patient wants.

How to Start Peptide Therapy